Compare Ascendis Pharma A/S (ASND) vs Delta Air Lines, Inc. (DAL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Delta Air Lines, Inc. — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Delta Air Lines, Inc. trades at $86.6 (market cap $57.41B). The key difference: Delta Air Lines, Inc. is far larger — about 3.2× Ascendis Pharma A/S's market cap, and Delta Air Lines, Inc. pays a 0.89% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | DAL | |
|---|---|---|
Market Cap | $17.74B | $57.41B |
Sector | Health | Industrials |
52-Week High | $277.18 | $93.66 |
52-Week Low | $163.32 | $51.15 |
Enterprise Value | $18.11B | $72.73B |
Dividend Yield | — | 0.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Delta Air Lines (DAL) trades at $87.39, down 1.81% today, but maintains a bullish technical outlook with strong support at $86. The company reported Q2 2026 EPS of $2.45, beating estimates by 64%, driven by premium demand and World Cup traffic benefits. Revenue growth remains robust at 14% year-over-year, with a net income margin of 6.87%. Analysts are overwhelmingly bullish with an 82% buy rating and a $106.07 price target, implying 21% upside. Cash flow trends show consistent operational strength, with 2025 net cash flow at $1.08 billion.
DAL presents a compelling investment case with earnings momentum, reasonable valuation (P/E 14.49), and analyst confidence. Key risks include fuel cost volatility and competitive pricing pressure, but strong corporate travel demand and dividend growth support long-term value. The stock's current dip offers a potential entry point near technical support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →
